23.27USD+1.77%Mkt Cap: 838.87M USDP/E: —Last update: 2026-05-26
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap838.87M USD
Enterprise Value645.88M USD
Revenue (TTM)10.00M USD
Gross Profit10.00M USD
Net Income (TTM)-68.87M USD
Revenue/Share0.7060 USD
Last Price23.27 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.07
PEG—
EV/EBITDA-7.29
EV/Revenue64.59
P/S84.82
P/B2.79
EPS (TTM)-2.11
EPS (Forward)-3.33
52W Range
13.8849% of range33.20
52W High33.20 USD
52W Low13.88 USD
Profitability
Gross Margin100.00%
Oper. Margin-899.93%
EBITDA Margin0.00%
Profit Margin-529.77%
ROE-33.50%
ROA-30.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.44M USD
CapEx (TTM)235.00K USD
FCF Margin-575.26%
FCF Yield-6.86%
Net Debt-202.35M USD
Net Debt/EBITDA2.28
Balance Sheet
Debt/Equity0.01
Current Ratio20.36
Quick Ratio19.94
Book Value/Sh8.456 USD
Cash/Share5.871 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)52.25 USD
Target Range50.00 USD – 55.00 USD
# Analysts8
Ownership
Shares Out.36.02M
Float19.96M
Insiders7.98%
Institutions110.45%
Short Interest
Short Ratio11.8d
Short % Float13.40%
Short % Out.9.02%
Shares Short3.25M
Short (prev mo.)3.31M
Technical
SMA 5024.25 (-4.0%)
SMA 20022.09 (+5.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)346.46K
Avg Vol (10d)433.21K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—